Including non-concurrent control patients in the analysis of platform trials: is it worth it? (2020)
Attributed to:
Developing efficient perpetual platform trials to study multiple treatments and multiple biomarkers
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.54280
Publication URI: https://www.repository.cam.ac.uk/handle/1810/307184
Type: Other